Hyaluronic acid filler / Allergan Aesthetics · AbbVie
Juvéderm Voluma XC
An exact formulation, an evolving US indication set, and two-year patient-reported outcomes.
Product Atlas · September 2026
The exact product comes first
Scope of this monograph#
VOLUMA XC, US. Other Juvéderm formulations and regional Voluma presentations require their own dossiers.
Clinical statements below summarize the attached documents. They are not a complete prescribing label. Match the exact local product and current instructions to the clinical decision.
Composition & formulation#
The original FDA label specifies crosslinked HA at 20 mg/mL and 0.3% lidocaine. The document is dated October 2013.[2]
How it works#
A viscoelastic HA gel provides physical tissue augmentation; material and tissue interaction influence the result.[2]
Indications & treatment areas#
Current US manufacturer information lists cheek volume loss, chin augmentation and moderate-to-severe temple hollowing in adults over 21. The original label covers cheeks only.[3][2]
Application considerations#
Use the current indication-specific instructions and anatomical plane. A historical cheek protocol cannot be reused for the temple.[2][3]
Contraindications & precautions#
Severe allergies, relevant bacterial-protein sensitivity and lidocaine allergy are contraindications. Defer treatment at sites with active inflammation or infection.[2]
Adverse effects & safety#
Tenderness, swelling, bruising and nodules are reported. Intravascular injection can cause necrosis, visual loss or stroke.[2][3]
Duration & follow-up#
A midface study reported patient-rated improvement in 79% at two years. This is not a guarantee for every patient or another anatomical site.[4]
Distinctions that matter#
Voluma, Volbella, Volux and Ultra XC have distinct US indications. A shared brand family is not evidence of equivalent handling or outcomes.[3]
Four markets. Separate evidence.#
Documents below identify what has been attached in this research edition. “Source needed” means unverified here; it is not a statement that a product is unapproved.
A current, exact-product local label or regulatory record has not yet been reconciled in this edition. Regulatory status is unverified here.
Contribute a local source ↗A current, exact-product local label or regulatory record has not yet been reconciled in this edition. Regulatory status is unverified here.
Contribute a local source ↗Original FDA label plus current manufacturer indication summary. Updated indication-specific IFUs remain a reconciliation item.[2][3]
Australian IFU attached for this regional presentation. US cheek, chin and temple indications are not transferred automatically.[1]
Studies worth a closer look.#
What does “up to two years” mean?
State the anatomical site, endpoint and responder proportion with a duration claim.
A closer look at the collagen story.
Biological activity is an evidence layer, not a substitute for clinical outcomes.
Follow the evidence.#
Retrieved 6 September 2026. A retrieval date does not establish that an older document is the latest approved revision. Studies marked “abstract” have not completed full-text appraisal.
- [1] VOLUMA with Lidocaine Australian instructions for use ↗Allergan Aesthetics · label · Document accessed · Checked 2026-09-06
- [2] VOLUMA XC original US directions for use ↗FDA / Allergan · label · Document accessed · Document: October 2013 — historical label · Checked 2026-09-06
- [3] JUVÉDERM US product information and approved uses ↗Allergan Aesthetics / AbbVie · manufacturer · Document accessed · Checked 2026-09-06
- [4] VOLUMA XC — patient-reported outcomes at two years ↗Aesthetic Surgery Journal, 2015 · PMID 25964628 · study · Abstract accessed · Checked 2026-09-06
Cite this monograph#
Aesthetic Pass. Juvéderm Voluma XC. Product Atlas research edition 2026.09.06.1. https://aestheticpass.com/products/monographs/juvederm-voluma-xc/